In the program.

Colectomy need in sufferers with serious ulcerative colitis drastically reduced by Kappaproct InDex Pharmaceuticals today announced the publication of positive data from the business’s compassionate use program using its lead compound Kappaproct . In the program, eight treatment-refractory ulcerative colitis sufferers that were elected for colectomy received Kappaproct, a DNA-centered immunomodulatory sequence targeting the toll-like receptor 9 . The findings showed that Kappaproct induced a pronounced and quick reduction in the colitis activity index for all treated individuals within 1 week following a single intracolonic administration. Further improvements were obvious at week 4, producing a clinical response rate after a single-dosage treatment with Kappaproct of 71 percent, with 43 percent in scientific remission.